Last reviewed · How we verify

NCT01178203

The Effects of Three Oral Medications on Post-operative Pain Following Endodontic Treatment

Completed Phase 1/Phase 2 Last updated 9 August 2010
What this trial tests

Phase 1/Phase 2 trial testing Placebo in Pulpitis. Completed in 1 August 2010.

Timeline
1 July 2010
Primary endpoint
1 July 2010
1 August 2010

Quick facts

Lead sponsorAzad University of Medical Sciences
PhasePhase 1/Phase 2
StatusCompleted
Study typeINTERVENTIONAL
Designparallel
Primary purposetreatment
Start date1 July 2010
Primary completion1 July 2010
Estimated completion1 August 2010

Drugs / interventions tested

Conditions studied

Sponsor

Azad University of Medical Sciences

Who can join

Adults 20 to 60, any sex, with Pulpitis or Pain Management.

Sponsor's own description

Aim: eliminating or reducing pain following endodontic treatment is of great importance. The aim of this study is to compare the effects of Tramadol, Novafen and Naproxen on post-operative pain following instrumentation of root canals in teeth with irreversible pulpitis. Sample size: one hundred patients considering the inclusion and exclusion criteria were selected. Intervention and outcome: The effect of Tramadol, Novafen and Naproxen on post-operative pain following instrumentation of root canals in teeth with irreversible pulpitis was evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Tramadol

Trials testing the same drug.

Other recruiting trials for Pulpitis

Currently open trials in the same condition.

Other Azad University of Medical Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01178203.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing